key: cord-0823623-c8fo8m3g authors: Al Rawahi, Bader; Al Wahaibi, Adil; Al Khalili, Sulien; Al Balushi, Ahmed Yar Mohammed; Al-Shehi, Nawal; Al Harthi, Khalid; Al-Abri, Seif title: Perspective: the impact of the acceleration of COVID-19 vaccine deployment in two border regions in Oman date: 2022-03-31 journal: IJID Regions DOI: 10.1016/j.ijregi.2022.03.020 sha: 6703865d4830beae00d99be3e591766c765ea661 doc_id: 823623 cord_uid: c8fo8m3g Background Among the challenges imposed by COVID-19 to public health systems was vaccine scarcity and prioritizing the high-risk groups. This prompted countries to accelerate the pace of immunization campaigns against COVID-19 to deploy the immunization umbrella to the largest possible number of target groups. In this paper, we share Oman's perspective on the impact of accelerating the administration of the first dose of the COVID-19 vaccine in one border governorate, Musandam, compared to another, Al-Buraimi, where measures were not implemented. Methods Daily admission data (10 April 2020–24 June 2021) and vaccination data (1 January–24 June 2021) were systematically collected. For each governorate, cumulative doses (first and second doses) and vaccination coverage were calculated daily. Results Within one month, first dose vaccination coverage increased from 20%–58% in Musandam reducing the incidence of hospital admission by 75% compared to Al-Buraimi where vaccination coverage plateaued at 20% and the incidence of hospital admission increased by 500% . Conclusions Given the peculiarity of geographical location and being the first line of access for imported cases, border regions should have priority for vaccine deployment as a preventive measure. Our two different approaches, implemented in broadly similar cross-border governorates, provided evidence of the significant effect of accelerating the first dose of vaccine in reducing hospitalization. We watched the success of the United Kingdom COVID-19 vaccination program in which the high vaccine effectiveness from a single dose justified their approach of rapidly offering the vaccine to a wider proportion of the population (Bernal et al., 2021; Government of United Kingdom, 2021; Harnden and Earnshaw, 2021) . We share our perspective from Oman, where the acceleration of the first dose of COVID-19 vaccine delivery in one border district, Musandam, clearly led to a significant reduction in COVID-19 incidence of hospitalizations compared to a broadly similar border district, Al-Buraimi, where this approach was not applied. The Sultanate of Oman, a country with a population of 4.6 million, has a unique location in the Middle East, sharing land borders with three countries (the Kingdom of Saudi Arabia, Yemen, and the United Arab Emirates (UAE)) and connected closely to other countries. These connections serve social, commercial, religious, tourism, and employment purposes. Al-Buraimi and Musandam governorates are located on the northern border of Oman with a total population of 49,457 and 122,114 in Musandam and Al-Buraimi respectively. 1 They are considered high-risk areas for SARS-CoV-2 introduction and spread due to their proximity to UAE and numerous land crossings between the two countries. Population movement across the borders to the UAE for employment and social purposes is a common part of life. Hence, influencing risk assessment, preparedness, and management throughout the pandemic, including COVID-19 vaccine deployment speed, is vital in view of vaccine scarcity in Oman. Musandam, unlike Al-Buraimi, is only accessible to the rest of Oman through passage via the UAE by land, sea, or domestic airlines. Public and private healthcare facilities were stretched due to the acceleration of the COVID-19 cases, and the government of Oman decided to prioritize the vaccination of its population in Musandam by vaccinating all over 18 years old starting at the end of January 2021. The aim of this study is to compare the effects of the speed of vaccine deployment on the impact of COVID-19 admissions in these two border governorates, Musandam and Al-Buraimi. Systematically collected daily admission data were used from 10 April 2020 to 24 June 2021 and vaccination data from 1 January 2021 to 24 June 2021. Cumulative doses (for the first and second doses) were calculated for each governorate each day. Vaccination coverage for each day was calculated by dividing the cumulative doses with the population over age 20 in the governorate. 1 The data was collected by vaccination date; therefore, we moved it to a twoweek period so that it represented cumulative coverage of full vaccination status. Results are presented graphically in Figure 1 , which compares hospitals admission incidence trends in Al-Buraimi and Musandam governorates in relation to the respective levels of vaccination coverage per governorate. Figure 1 shows that the maximum vaccination coverage for the first dose was 58% and 23% for Musandam and Al-Buraimi, respectively. It also shows the effect of faster vaccine deployment in Musandam (first dose vaccination coverage increased from 20% to 58% within one month) compared to Al-Buraimi (vaccination coverage plateaued at 20% within the same month) that has greatly reduced the COVID-19 related hospital admission incidence by 75% (from 40 to 10 per 100,000 population) in Musandam compared to increase in the same incidence by 500% in Buraimi (from 10 to 60 per 100,000 population). COVID-19 has inflicted major damage worldwide in terms of morbidity and mortality despite the interventions designed to reduce its spread and impact, from curfews to masking, quarantining to institutional closures, necessitating a working and well distributed vaccine In Oman, when the vaccine rollout started in December 2020, it initially targeted health care workers, front-line staff and people with co-morbid conditions such as chronic lung or renal diseases and obesity. The pandemic's progression with widespread variant importation posed challenges to control the disease which was further aggravated by the limitation to vaccine access in some countries (Iftekhar et al, 2021) . Oman has prioritized the groups who must receive the vaccine due to the initial supply limitation and high demand, this strategy was also based on a national study by Al Wahaibi et al on COVID-19 severity and mortality determinants in Oman (2021). Subsequently, a strategy to cover 70% of the total population was set with a deployment plan for administering the vaccine in two phases by priority groups (30% starting in late 2020, then 40% from July to October 2021). This was achieved through the establishment of mega vaccination centers in different governorates with the partnership of the private sector. However, due to the lack of vaccine production and the trouble in receiving the booked amounts of the vaccine from COVAX, Oman purchased the vaccine directly from vaccine manufacturers at much higher prices than the quantities booked through COVAX. Although pillars of preventive measures during the COVID-19 pandemic remain the same, special attention, prioritization, and faster vaccine deployment should be given to border The effect of faster vaccine deployment in Musandam with its prioritized one dose strategy compared to the approach taken in Al-Buraimi provided evidence of the significant impact of such tactics in the reduction of COVID-19 related admission incidence, similar to experiences from other countries (Wise, 2021; Roghani, 2021) . This study provided significant evidence that the effect of accelerating the COVID-19 vaccination (even with one dose) reduces the COVID-19 related incidence of hospitalizations and could be the cause of reduction in death due to COVID-19 in the population of Musandam compared to Al-Buraimi. ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Molecular epidemiology of COVID-19 in Oman: A molecular and surveillance study for the early transmission of COVID-19 in the country COVID-19 disease severity and mortality determinants: A large population-based analysis in Oman Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England Lessons from the United Kingdom's COVID-19 vaccination strategy Critical prerequisites for COVID-19 vaccine acceleration: A developing economy perspective A look into the future of the COVID-19 pandemic in Europe: an expert consultation The impact of vaccination on COVID-19 outbreaks in the United States Published letter regarding "Acceleration of second doses for all cohorts The influence of COVID-19 vaccination on daily cases, hospitalization, and death rate in Tennessee, United States: case study COVID-19: Is vaccination roll out reducing cases and deaths in the UK?